Minimize Menorrhagia in Women With Von Willebrand Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This is an outpatient, 24-week Phase III prospective, randomized, crossover trial comparing recombinant von Willebrand factor (rVWF) and tranexamic acid (TA, Lysteda®) to minimize menorrhagia in women with von Willebrand disease (VWD). The purpose of this Phase III multicenter prospective, randomized, crossover arm trial is to compare recombinant von Willebrand factor (rVWF) to tranexamic acid (TA) in reducing the severity of menorrhagia in women with von Willebrand disease.
Epistemonikos ID: 2266d5c1e8f1ae9b85b0613b91615294a7d1e9a9
First added on: May 12, 2024